Meditoxin

Product Overview

MEDITOXIN is a South Korean botulinum toxin type A injectable medicine developed and manufactured by Medytox Inc. Available in MEDITOXIN 100 Units and MEDITOXIN 200 Units, the product contains Clostridium botulinum toxin type A derived from the Hall strain, with human serum albumin and sodium chloride as excipients. Both strengths are supplied as white lyophilized powder in single-dose glass vials.

MEDITOXIN is a prescription neuromodulator that temporarily inhibits acetylcholine release at peripheral cholinergic nerve terminals. By reducing neuromuscular signaling, botulinum toxin type A produces temporary relaxation of affected skeletal muscles.

First authorized in South Korea in 2006, MEDITOXIN is one of the country's established botulinum toxin type A pharmaceutical brands. The product is also marketed internationally under the Neuronox name in certain countries, subject to market-specific regulatory approvals and labeling.

The 100U and 200U formulations share the same active ingredient and general pharmaceutical characteristics. Their primary difference is the labeled biological potency contained in each vial.

This TEOSQUARE product page covers MEDITOXIN 100U and 200U, providing professional buyers with information about composition, formulation characteristics, vial strengths, packaging, storage requirements, and regulatory considerations.

Key Features

• Botulinum Toxin Type A: Contains Clostridium botulinum toxin type A derived from the Hall strain, a neurotoxic protein that temporarily inhibits acetylcholine release at susceptible nerve terminals.
• 100U and 200U Strengths: Available in two labeled potency presentations, each containing a different quantity of product-specific biological activity.
• Lyophilized Pharmaceutical Formulation: Supplied as white freeze-dried powder in a colorless transparent glass vial.
• Albumin-Containing Composition: Formulated with human serum albumin and sodium chloride as pharmaceutical excipients.
• Single-Vial Packaging: Both MEDITOXIN 100U and 200U are supplied in manufacturer-documented packages containing one vial per box.
• South Korean Pharmaceutical Manufacturer: Manufactured by Medytox Inc., a biotechnology company specializing in botulinum toxin pharmaceutical products.

Composition & Specifications

MEDITOXIN contains Clostridium botulinum toxin type A derived from the Hall strain as its active pharmaceutical ingredient. Human serum albumin and sodium chloride are included as excipients.

The 100U and 200U strengths indicate the total labeled biological potency per vial. These units are specific to the product's potency measurement system and must not be interpreted as protein mass or directly interchangeable with units from other botulinum toxin preparations.

Clostridium Botulinum Toxin Type A

Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum. Pharmaceutical formulations contain controlled quantities of the toxin, which temporarily inhibit neurotransmitter release at susceptible peripheral nerve terminals.

MEDITOXIN uses botulinum toxin type A derived from the Hall strain. This bacterial strain is associated with established pharmaceutical manufacturing processes for selected botulinum toxin preparations.

The toxin's pharmacological action involves interference with the cellular machinery responsible for acetylcholine release. This reduces the transmission of signals from motor neurons to skeletal muscle fibers.

MEDITOXIN potency is expressed in biological units rather than milligrams. The number of units identifies the measured biological activity within a vial, not the molecular weight or mass of the toxin protein.

Human Serum Albumin

Human serum albumin is a plasma-derived protein used as a stabilizing excipient in certain biological pharmaceutical formulations.

It may help maintain protein stability during manufacturing, lyophilization, storage, and handling.

Both MEDITOXIN 100U and 200U contain human serum albumin. The exact excipient quantities should be verified using the official prescribing information for the selected strength.

Sodium Chloride

Sodium chloride is included as an excipient contributing to the formulation's physicochemical characteristics.

Its presence is documented in the South Korean pharmaceutical registration information for both MEDITOXIN strengths.

MEDITOXIN 100U and 200U share the same identified active ingredient and excipient categories. Exact quantitative formulation details and current specifications should be confirmed using the official documentation for each supplied product.

How MEDITOXIN Botulinum Toxin Type A Works

MEDITOXIN temporarily reduces neuromuscular transmission by inhibiting acetylcholine release from peripheral cholinergic nerve terminals. This mechanism is characteristic of botulinum toxin type A pharmaceutical products.

Neuromuscular Signal Transmission

Under normal physiological conditions, motor neurons release acetylcholine at the neuromuscular junction. Acetylcholine binds to receptors on skeletal muscle fibers and initiates electrical signaling that leads to muscle contraction.

Botulinum toxin type A interferes with this process by acting within susceptible nerve terminals.

SNAP-25 Cleavage

Botulinum toxin type A contains an enzymatically active light chain that cleaves SNAP-25, a protein involved in the SNARE complex responsible for neurotransmitter vesicle fusion.

Disruption of SNAP-25 function reduces the release of acetylcholine into the neuromuscular junction.

As a result, the affected muscle receives fewer stimulatory signals from its motor nerve terminals.

Temporary Muscle Relaxation

Reduced acetylcholine release produces temporary relaxation or weakness of the affected skeletal muscles.

In approved aesthetic applications, this mechanism can reduce the appearance of certain facial wrinkles associated with repeated muscle contraction.

The effects are temporary because neuromuscular function can gradually recover over time through biological processes involving nerve-terminal recovery and restoration of neurotransmission.

Clinical Effect and Duration

The onset, magnitude, and duration of the clinical effect depend on the product formulation, approved indication, administration conditions, and individual patient characteristics.

A specific duration of action should not be assumed for every clinical application or patient solely from general botulinum toxin type A research.

These mechanisms describe established botulinum toxin type A pharmacology. They do not demonstrate identical clinical performance, duration, or dose equivalence between MEDITOXIN and other botulinum toxin brands.

Available MEDITOXIN Variants

MEDITOXIN is available in several registered strengths. This TEOSQUARE product group covers MEDITOXIN 100 Units and MEDITOXIN 200 Units.

Both formulations contain Clostridium botulinum toxin type A derived from the Hall strain and are supplied as lyophilized powder in single-dose glass vials.

The main distinction between these two variants is the total labeled biological potency contained in each vial.

MEDITOXIN 100 Units

MEDITOXIN 100U contains 100 units of Clostridium botulinum toxin type A derived from the Hall strain.

The formulation is supplied as white lyophilized powder in a colorless transparent glass vial, with one vial per manufacturer box.

MEDITOXIN 100U received its initial South Korean pharmaceutical authorization on March 16, 2006, under product authorization code 200600841.

The product contains human serum albumin and sodium chloride as excipients and is classified as a prescription medicine.

MEDITOXIN 200 Units

MEDITOXIN 200U contains 200 units of Clostridium botulinum toxin type A derived from the Hall strain.

Like the 100U formulation, MEDITOXIN 200U is supplied as white lyophilized powder in a glass vial and contains human serum albumin and sodium chloride.

MEDITOXIN 200U received its initial South Korean pharmaceutical authorization on March 31, 2009, under product authorization code 200902348.

The 200U presentation contains twice the labeled total biological potency of the 100U vial. This does not mean that each unit has greater potency, produces a stronger clinical effect, or requires a different mechanism of action.

The 100U and 200U strengths are distinct commercial pharmaceutical presentations. Product selection and clinical use must follow the applicable prescribing information. Botulinum toxin potency units are not directly interchangeable between brands.

Approved Indications & Clinical Applications

MEDITOXIN is registered in South Korea as a prescription botulinum toxin type A pharmaceutical product.

Its South Korean prescribing information identifies both aesthetic and therapeutic indications.

Temporary Improvement of Glabellar Lines

MEDITOXIN is indicated in South Korea for the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 20 to 65 years.

Glabellar lines are facial expression wrinkles that develop between the eyebrows through repeated contraction of the associated muscles.

Botulinum toxin type A temporarily reduces the activity of these muscles by inhibiting neuromuscular transmission.

Benign Essential Blepharospasm

MEDITOXIN is also indicated in South Korea for the treatment of benign essential blepharospasm in adults aged 18 years or older.

Blepharospasm is a neurological movement disorder characterized by involuntary contractions of muscles surrounding the eyes.

Spastic Equinus Foot Deformity

The South Korean product information includes treatment of equinus foot deformity associated with spasticity in pediatric cerebral palsy patients aged two years or older.

This therapeutic application involves the product's ability to temporarily reduce excessive muscle activity.

Post-Stroke Upper Limb Spasticity

MEDITOXIN is also registered in South Korea for the treatment of focal upper limb spasticity associated with stroke in adults aged 20 years or older.

Spasticity is characterized by abnormal muscle stiffness and increased resistance to passive movement associated with neurological injury.

These indications reflect South Korean pharmaceutical information. Authorization may differ by country, product strength, and regulatory version. Applications outside the officially approved indications require separate legal and clinical assessment.

Packaging & Product Presentation

MEDITOXIN 100U and 200U are supplied as lyophilized pharmaceutical formulations in individual glass vials.

The manufacturer-documented packaging contains one vial per box for each strength. The product is presented as a white freeze-dried powder rather than a ready-to-use liquid solution.

The labeled potency indicates the total biological activity of the product contained in the vial. It is not a liquid volume or a recommended administration quantity.

Packaging appearance may differ between domestic and export markets. Buyers should verify the complete product name, labeled strength, original manufacturer details, batch number, expiration date, and applicable regulatory information.

MEDITOXIN and Neuronox are associated with Medytox's botulinum toxin product portfolio, but market-specific names and packaging must be checked individually. Commercial naming does not establish that products from different markets may be freely substituted or imported.

Storage & Handling

Medytox and South Korean pharmaceutical registration information specify two permitted storage conditions for unopened MEDITOXIN 100U and 200U vials: frozen storage between -15°C and -5°C or refrigerated storage between 2°C and 8°C.

The product must be maintained in its original sealed container under the temperature conditions permitted by its labeling.

• Refrigerated Storage: Store between 2°C and 8°C under the manufacturer's labeled conditions.
• Permitted Frozen Storage: The South Korean labeling also identifies -15°C to -5°C as an approved storage range for unopened vials.
• Original Container: Maintain the product in its hermetically sealed vial and original manufacturer packaging.
• Temperature-Controlled Distribution: Transport and store the product under conditions consistent with its official pharmaceutical labeling.
• Packaging Integrity: Inspect the original vial and packaging for signs of damage or compromised integrity.
• Product Traceability: Verify the product strength, batch number, expiration date, manufacturer identification, and applicable release documentation.

Storage requirements for a prepared solution are different from those for unopened lyophilized vials. Preparation, handling after preparation, and disposal must comply with the official prescribing information.

The permitted frozen and refrigerated ranges apply to unopened products under the relevant South Korean labeling. Do not assume that storage conditions for other botulinum toxin formulations are interchangeable with MEDITOXIN.

Safety & Regulatory Considerations

MEDITOXIN is a prescription biological medicine containing botulinum toxin type A. Its use requires appropriate medical supervision and compliance with product-specific indications, contraindications, warnings, and prescribing regulations.

Potential Adverse Reactions

Adverse reactions associated with botulinum toxin type A products may include injection-site pain, bruising, swelling, headache, and unintended weakness of nearby muscles.

Depending on the indication and anatomical location, additional reactions may include eyelid ptosis, facial asymmetry, or other functional changes caused by unintended neuromuscular effects.

Potential Spread of Toxin Effects

Botulinum toxin products may cause serious adverse reactions if toxin effects spread beyond the intended administration area.

Reported complications associated with this drug class include generalized muscle weakness, difficulty swallowing, speech disturbances, and breathing difficulties.

Such reactions can be medically serious and require immediate professional assessment.

Contraindications and Precautions

Patients with known hypersensitivity to botulinum toxin type A or formulation components, or infection at the proposed administration site, may have contraindications to treatment.

Individuals with certain neuromuscular disorders or those taking medications that affect neuromuscular transmission may require additional precautions.

MEDITOXIN contains human serum albumin, and applicable safety information relating to biological excipients should be reviewed.

Non-Interchangeable Potency Units

Botulinum toxin potency units are established using product-specific biological assay methods.

MEDITOXIN units must not be directly converted into units of BOTOX, Dysport, Xeomin, or another botulinum toxin product without appropriate product-specific evidence and authorization.

Regulatory Authorization and Distribution

MEDITOXIN is registered as a prescription pharmaceutical product in South Korea. Its regulatory history includes administrative proceedings and subsequent court decisions concerning certain product strengths.

Professional buyers should verify the current authorization status, applicable manufacturing and distribution restrictions, national lot-release requirements, and original product documentation before procurement.

South Korean pharmaceutical authorization does not automatically establish approval in the United States, European Union, or other countries. The legal status of MEDITOXIN and its internationally marketed counterparts must be evaluated separately in each destination market.

This information is intended for professional product identification and comparison. It does not provide dosing or administration instructions, replace official prescribing information, establish patient suitability, or authorize distribution outside applicable pharmaceutical regulations.

Frequently Asked Questions